RecruitingNCT07473804

Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)


Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

25 participants

Start Date

Apr 14, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Neonatal salt loss can be caused not only by infections but also by rare endocrine disorders that resemble 21-hydroxylase deficiency but are not detected by neonatal screening. This study examines how often these conditions occur and describes their main clinical, genetic, and treatment features.


Eligibility

Min Age: 1 YearMax Age: 35 Years

Inclusion Criteria4

  • Patients with a diagnosis of endocrine-related salt loss, defined by laboratory findings of hyponatremia (serum sodium \<130 mEq/L)
  • Age at onset of salt loss between 0 and 60 days of life
  • Patients born between January 1, 1989 and December 31, 2023 and managed at the Experimental Center
  • Obtained Informed consent

Exclusion Criteria1

  • • Diagnosis of 21OH ISC

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07473804


Related Trials